It is desirable to measure PD-L1 expression by 28-8 kit in determining whether or not the following drugs can be administered.
・Nivolumab [recombinant] for the patients with non-squamous NSCLC patients or head-and-neck cancer patients who have been treated with chemotherapy previously.
・Combination therapy of nivolumab [recombinant] and chemotherapy for NSCLC patients or gastric cancer patients who have not been treated with chemotherapy.
・Combination therapy of nivolumab [recombinant] and ipilimumab for melanoma patients.
If it is not possible to measure PD-L1 expression using 28-8 kit, refer to the packaging insert of the drugs, and appropriately judge the adequacy of administration.
*See the OPDIVO® and YERYOV® product labels for specific clinical circumstances guiding PD-L1 testing.PD-L1 IHC 28-8 pharmDx
The kit includes reagents required for the immunohistochemical staining (except wash buffer), control slides representing differentexpression levels of PD-L1 protein, and detailed instructions. The kit has been tailored especially for use on Autostainer Link 48 instruments. The materials provided are sufficient for 50 tests (50 slides incubated with monoclonal rabbit antibody to PD-L1 and 50 slides incubated with the corresponding Negative Control Reagent, 100 slides in total).
PD-L1 IHC 28-8 pharmDx is subject to an exclusive trademark license to Agilent Technologies, Inc. OPDIVO® is a trademark owned by ONO in Japan, Korea and Taiwan and by Bristol-Myers Squibb in the rest of the world. YERVOY® is a trademark owned by Bristol-Myers Squibb.